Trastuzumab is offered to, and lapatinib is in clinical trial for, patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer [11], [12], and inhibitors that target hepatocyte growth factor receptor (c-Met) and fibroblast growth factor receptors (FGFRs) are under clinical trial [13]. This evidence concerns the gene MET and gastric cancer.